Opportunity Information: Apply for EDS EDS 25 001
The Drug Supply in Biological Specimens from Emergency Departments opportunity (Funding Opportunity Number: EDS EDS 25 001) is a discretionary federal funding program from the Office of National Drug Control Policy that will support a single, targeted research effort aimed at strengthening how communities and the nation monitor and respond to the drug crisis. The project centers on using biological specimens collected through emergency departments as a way to better understand what substances are actually being consumed in real time, including emerging or rapidly changing drug mixtures that may not be captured well through other reporting channels.
At its core, the grant is meant to improve drug consumption surveillance at both local and national levels. By analyzing biological specimens associated with emergency department encounters, the funded work is expected to generate clearer, more current signals about drug exposure patterns and shifts in the drug supply. This kind of surveillance can help decision-makers move beyond assumptions based on self-report, law enforcement seizures, or delayed mortality data, and instead ground public health and safety actions in evidence of what is showing up in patients.
A major emphasis is identifying gaps in existing drug testing protocols. Many hospitals and clinical labs rely on standard toxicology panels that may miss newer synthetic opioids, novel benzodiazepines, adulterants, or other emerging substances, or may lack the specificity needed to distinguish closely related compounds. The funded project is intended to examine where current testing practices fall short and to inform improvements so that testing better reflects today’s drug market and supports more accurate situational awareness.
The opportunity also prioritizes facilitating information exchange across public health and public safety organizations. Drug trends often cross systems: hospitals see overdoses and adverse events, public health agencies track outbreaks and population risk, and public safety organizations may have intelligence on trafficking patterns or local supply changes. This cooperative agreement is designed to help connect those dots by improving how findings from emergency department specimen testing are shared, communicated, and translated into actionable information across partners, while supporting coordination rather than siloed responses.
Another intended outcome is better coordination of an informed response to the drug crisis. With stronger surveillance and clearer testing information, communities can more quickly adjust prevention messaging, harm reduction strategies, clinical guidance, and resource allocation. The project is positioned to help stakeholders respond to changing conditions, such as spikes tied to fentanyl analogs, counterfeit pills, xylazine or other adulterants, or regional shifts in polysubstance use, by providing more timely and credible evidence drawn from hospital-based data.
Funding is provided through a cooperative agreement, which generally indicates substantial involvement by the federal agency during the project period, such as collaboration on project direction, methods, deliverables, or dissemination. The award ceiling is $400,000, and only one award is expected, suggesting the sponsor is seeking a focused effort that can serve as a model, proof of concept, or high-impact pilot with broader applicability.
Eligible applicants include public and state-controlled institutions of higher education, private institutions of higher education, and nonprofit organizations with 501(c)(3) status (other than institutions of higher education), as well as other eligible entities as allowed in the announcement. The activity category is Health, and the CFDA/Assistance Listing number is 95.007. The opportunity was created on 2025-08-14, and the original application closing date is 2025-09-05.
Overall, this grant is aimed at using hospital emergency department biological specimen testing as a practical and evidence-driven way to improve drug surveillance, modernize and close gaps in toxicology testing practices, strengthen cross-sector information sharing, and help communities coordinate faster, better-informed responses to a rapidly evolving drug environment.Apply for EDS EDS 25 001
- The Office of National Drug Control Policy in the health sector is offering a public funding opportunity titled "Drug Supply in Biological Specimens from Emergency Departments" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 95.007.
- This funding opportunity was created on 2025-08-14.
- Applicants must submit their applications by 2025-09-05. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Each selected applicant is eligible to receive up to $400,000.00 in funding.
- The number of recipients for this funding is limited to 1 candidate(s).
- Eligible applicants include: Public and State controlled institutions of higher education, Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education, Private institutions of higher education, Others.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Frequently Asked Questions (FAQs)
What is the "Drug Supply in Biological Specimens from Emergency Departments" opportunity?
This is a discretionary federal funding opportunity from the Office of National Drug Control Policy (ONDCP) focused on a single, targeted research effort. The project is designed to strengthen how communities and the nation monitor and respond to the drug crisis by analyzing biological specimens associated with emergency department encounters.
What is the Funding Opportunity Number for this program?
The Funding Opportunity Number is EDS EDS 25 001.
What type of award is this (grant vs. cooperative agreement)?
Funding is provided through a cooperative agreement. This generally means the federal agency is expected to have substantial involvement during the project period, such as collaboration on project direction, methods, deliverables, and/or dissemination.
How many awards are expected?
Only one award is expected, indicating the sponsor is seeking a focused effort that can serve as a model, proof of concept, or high-impact pilot with broader applicability.
What is the maximum award amount?
The award ceiling is $400,000.
What is the main purpose of the funded project?
The main purpose is to improve drug consumption surveillance at local and national levels by analyzing biological specimens connected to emergency department encounters. The intent is to produce clearer, more current signals about drug exposure patterns and shifts in the drug supply.
Why focus on emergency department biological specimens?
Emergency departments can provide near real-time insight into what substances are actually showing up in patients. Specimen-based findings can help reveal emerging or rapidly changing drug mixtures that may not be well captured through other channels.
What kinds of drug trend signals is this project aiming to produce?
The project is aimed at detecting drug exposure patterns and shifts in the drug supply, including emerging substances and changing mixtures. It is intended to generate timely, credible evidence grounded in hospital-based specimen testing.
How does this approach differ from other drug surveillance methods?
The opportunity emphasizes moving beyond assumptions based on self-report, law enforcement seizure data, or delayed mortality data by using evidence from biological specimens associated with emergency department encounters.
What specific gap is the project expected to address in hospital or clinical laboratory testing?
A major emphasis is identifying gaps in existing drug testing protocols. Many standard toxicology panels may miss newer synthetic opioids, novel benzodiazepines, adulterants, or other emerging substances, or may lack specificity to distinguish closely related compounds. The project is intended to examine where current practices fall short and inform improvements.
What types of substances are highlighted as potentially being missed by standard toxicology panels?
The description highlights newer synthetic opioids, novel benzodiazepines, adulterants, and other emerging substances. It also notes the challenge of distinguishing closely related compounds when testing lacks sufficient specificity.
Is improving toxicology testing practices part of the intended outcomes?
Yes. The funded project is intended to identify shortcomings in current testing practices and inform improvements so testing better reflects the current drug market and supports more accurate situational awareness.
What does the opportunity say about information sharing across sectors?
The opportunity prioritizes facilitating information exchange across public health and public safety organizations. It is designed to improve how findings from emergency department specimen testing are shared, communicated, and translated into actionable information across partners, supporting coordination rather than siloed responses.
Which systems or stakeholders are described as needing better connection and coordination?
The description specifically mentions hospitals (overdoses and adverse events), public health agencies (outbreaks and population risk), and public safety organizations (intelligence on trafficking patterns and local supply changes) as systems that often hold different pieces of the drug trend picture.
How is the funded work expected to help communities respond to the drug crisis?
With stronger surveillance and clearer testing information, communities can more quickly adjust prevention messaging, harm reduction strategies, clinical guidance, and resource allocation. The goal is to help stakeholders respond to changing conditions using timely evidence from hospital-based data.
What kinds of changing drug conditions does the opportunity mention?
Examples include spikes tied to fentanyl analogs, counterfeit pills, xylazine or other adulterants, and regional shifts in polysubstance use.
What is the activity category for this funding opportunity?
The activity category is Health.
What is the CFDA/Assistance Listing number?
The CFDA/Assistance Listing number is 95.007.
Who is eligible to apply?
Eligible applicants include public and state-controlled institutions of higher education, private institutions of higher education, and nonprofit organizations with 501(c)(3) status (other than institutions of higher education), as well as other eligible entities as allowed in the announcement.
Does the opportunity indicate whether institutions of higher education can apply?
Yes. Both public/state-controlled institutions of higher education and private institutions of higher education are listed as eligible applicants.
Are 501(c)(3) nonprofits eligible?
Yes. Nonprofit organizations with 501(c)(3) status (other than institutions of higher education) are listed as eligible applicants.
What is the application closing date?
The original application closing date is 2025-09-05.
When was this opportunity created?
The opportunity was created on 2025-08-14.
What does it mean that this is a "single, targeted research effort"?
Based on the description, the sponsor intends to fund one focused project that concentrates on emergency department specimen-based surveillance and related improvements in testing and information sharing, rather than multiple separate awards.
What role does ONDCP expect to play during the project?
Because the mechanism is a cooperative agreement, ONDCP is generally expected to be substantially involved during the project period, potentially collaborating on direction, methods, deliverables, or dissemination.
What is the overall goal of this funding opportunity?
Overall, the grant aims to use emergency department biological specimen testing to improve drug surveillance, modernize and close gaps in toxicology testing practices, strengthen cross-sector information sharing, and help communities coordinate faster, better-informed responses to a rapidly evolving drug environment.
Browse more opportunities from the same category: Health
Next opportunity: Applied Learning Experiences Related to Drug Control Policy
Previous opportunity: FY2025 - Historic Preservation Fund- Annual Tribal Historic Preservation Office Grants
Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for EDS EDS 25 001
Applicants also applied for:
Applicants who have applied for this opportunity (EDS EDS 25 001) also looked into and applied for these:
| Funding Opportunity |
|---|
| NIDCD Clinical Research Center Grant (P50 Clinical Trial Optional) Apply for PAR 25 445 Funding Number: PAR 25 445 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Mucosal Immunology Studies Team (MIST) (U01 Clinical Trial Not Allowed) Apply for RFA AI 25 018 Funding Number: RFA AI 25 018 Agency: National Institutes of Health Category: Health Funding Amount: $350,000 |
| Claude D. Pepper Older Americans Independence Centers (P30 Clinical Trial Optional) Apply for RFA AG 26 025 Funding Number: RFA AG 26 025 Agency: National Institutes of Health Category: Health Funding Amount: $925,000 |
| Tuberculosis Research Units (P01 Clinical Trial Optional) Apply for RFA AI 25 027 Funding Number: RFA AI 25 027 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Partnerships for Development of Vaccines to Prevent Mycobacterium tuberculosis Infection and/or Disease (R01 Clinical Trial Not Allowed) Apply for RFA AI 25 022 Funding Number: RFA AI 25 022 Agency: National Institutes of Health Category: Health Funding Amount: $750,000 |
| Nonhuman Primate Reagent Resource (U24 Clinical Trial Not Allowed) Apply for RFA AI 25 010 Funding Number: RFA AI 25 010 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Stimulating Access to Research in Residency (StARR) (R38 Independent Clinical Trial Not Allowed) Apply for RFA HL 26 012 Funding Number: RFA HL 26 012 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Native American Research Centers for Health (NARCH) Planning Grants (R34 - Clinical Trial Not Allowed) Apply for PAR 25 441 Funding Number: PAR 25 441 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Influenza Transmission Research Consortium (P01 Clinical Trial Optional) Apply for RFA AI 25 035 Funding Number: RFA AI 25 035 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| NIA Expanding Research in AD/ADRD (ERA) Postbaccalaureate Research Education Program (R25 Independent Clinical Trial Not Allowed) Apply for RFA AG 26 010 Funding Number: RFA AG 26 010 Agency: National Institutes of Health Category: Health Funding Amount: $400,000 |
| Artificial Intelligence and Technology Collaboratory Coordinating Center (U24 Clinical Trial Not Allowed) Apply for RFA AG 26 007 Funding Number: RFA AG 26 007 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| NIA Expanding Research in AD/ADRD (ERA) Summer Research Education Program (R25 Independent Clinical Trial Not Allowed) Apply for RFA AG 26 011 Funding Number: RFA AG 26 011 Agency: National Institutes of Health Category: Health Funding Amount: $200,000 |
| Artificial Intelligence and Technology Collaboratory (P30 Clinical Trial Optional) Apply for RFA AG 26 006 Funding Number: RFA AG 26 006 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Aging Mammalian Tissues In Vitro (R21 Clinical Trial Not Allowed) Apply for RFA AG 26 014 Funding Number: RFA AG 26 014 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Dental Preventive Clinical Support Apply for HHS 2026 IHS TDCP 0001 Funding Number: HHS 2026 IHS TDCP 0001 Agency: Indian Health Service Category: Health Funding Amount: $440,000 |
| Rural Health Transformation Program Apply for CMS RHT 26 001 Funding Number: CMS RHT 26 001 Agency: Centers for Medicare Medicaid Services Category: Health Funding Amount: Case Dependent |
| Fostering Collaboration Across Ryan White HIV/AIDS Programs (RWHAPs) to Engage People with HIV in Care Apply for HRSA 26 014 Funding Number: HRSA 26 014 Agency: Health Resources and Services Administration Category: Health Funding Amount: $1,500,000 |
| Optimizing Treatment Strategies for Adult Attention-Deficit Hyperactivity Disorder (ADHD) (R01 Clinical Trial Required) Apply for RFA MH 26 195 Funding Number: RFA MH 26 195 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Limited Competition: National Biocontainment Laboratories (NBLs) Operations Support (UC7 Clinical Trials Not Allowed) Apply for RFA AI 25 013 Funding Number: RFA AI 25 013 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Pilot Projects to Enhance the Human Virome Program (R03, Clinical Trials Not Allowed) Apply for RFA RM 25 006 Funding Number: RFA RM 25 006 Agency: National Institutes of Health Category: Health Funding Amount: $100,000 |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Inside Our Applicants Portal
Access Applicants Portal
- Grants Repository - Access current and historic funding opportunities with ease. Thousands of funding opportunities are published every week. We can help you sort through the database and find the eligible ones to apply for.
- Applicant Video Guides - The grant application process can be challenging to follow. We can help you with intuitive video guides to speed up the process and eliminate errors in submissions.
- Grant Proposal Wizard - We have developed a network of private funding organizations and investors across the United States. We can reach out and submit your proposal to these contacts to maximize your chances of getting the funding you need.
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Learn More
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "EDS EDS 25 001", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.